TY - JOUR T1 - C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON) JO - Archivos de Bronconeumología T2 - AU - Posadas,Tomás AU - Oscullo,Grace AU - Zaldivar,Enrique AU - Villa,Carmen AU - Dobarganes,Yadira AU - Girón,Rosa AU - Olveira,Casilda AU - Maíz,Luis AU - García-Clemente,Marta AU - Sibila,Oriol AU - Golpe,Rafael AU - Rodríguez,Juan AU - Barreiro,Esther AU - Rodriguez,Juan Luis AU - Menéndez,Rosario AU - Prados,Concepción AU - de la Rosa,David AU - Martinez-García,Miguel Angel SN - 15792129 M3 - 10.1016/j.arbr.2019.12.022 DO - 10.1016/j.arbr.2019.12.022 UR - https://www.archbronconeumol.org/en-c-reactive-protein-concentration-in-steady-state-articulo-S157921292030392X AB - BackgroundBoth systemic inflammation and exacerbations have been associated with greater severity of bronchiectasis. Our objective was to analyze the prognostic value of the peripheral concentration of C-reactive protein (CRP) for the number and severity of exacerbations in patients with bronchiectasis. MethodsPatients from the Spanish Bronchiectasis Registry (RIBRON) with valid data on their CRP value (in a clinically stable phase) and valid data on exacerbations during the first year of follow-up were included. A logistic regression analysis was used to evaluate the prognostic value of the CRP concentration (divided into tertiles) with the presence of at least one severe exacerbation or at least two mild-moderate exacerbations during the first year of follow-up. Results802 patients (mean age: 68.1 [11.1 years], 65% female) were included. Of these, 33.8% and 13%, respectively, presented ≥2 mild-moderate exacerbations or at least one severe exacerbation during the first year of follow-up. The mean value of the CRP was 6.5 (17.6mg/L). Patients with a CRP value between 0.4 and 2.7mg/L (second tertile) and ≥2.7mg/L (third tertile) presented a 2.9 (95%CI: 1.4–5.9) and 4.2 (95%CI: 2.2–8.2) times greater probability, respectively, of experiencing a severe exacerbation than those with <0.4mg/L (control group), regardless of bronchiectasis severity or a history of previous exacerbations. However, the CRP value did not present any prognostic value for the number of mild-moderate exacerbations. ConclusionsThe CRP value was associated with a greater risk of future severe exacerbations but not with mild or moderate exacerbations in patients with steady-state bronchiectasis. ER -